733 related articles for article (PubMed ID: 29035619)
1. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
[TBL] [Abstract][Full Text] [Related]
2. Characterization of asthma endotypes: implications for therapy.
Stokes JR; Casale TB
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539
[TBL] [Abstract][Full Text] [Related]
3. Emerging Biologics in Severe Asthma.
Pavord ID; Hilvering B; Shrimanker R
Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
[TBL] [Abstract][Full Text] [Related]
4. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
5. Recent Patents for the Treatment of Asthma.
El-Qutob D; Raducan I
Recent Pat Inflamm Allergy Drug Discov; 2016; 10(1):13-20. PubMed ID: 27262358
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for asthma.
Walsh GM
Expert Opin Emerg Drugs; 2008 Dec; 13(4):643-53. PubMed ID: 19046132
[TBL] [Abstract][Full Text] [Related]
7. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
Heffler E; Paoletti G; Giorgis V; Puggioni F; Racca F; Del Giacco S; Bagnasco D; Caruso C; Brussino L; Rolla G; Canonica GW
Expert Rev Clin Immunol; 2019 Sep; 15(9):951-958. PubMed ID: 31389304
[No Abstract] [Full Text] [Related]
8. Severe T2-high asthma in the biologics era: European experts' opinion.
Pavord I; Bahmer T; Braido F; Cosío BG; Humbert M; Idzko M; Adamek L
Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31285291
[TBL] [Abstract][Full Text] [Related]
9. Biologics in asthma--the next step toward personalized treatment.
Darveaux J; Busse WW
J Allergy Clin Immunol Pract; 2015; 3(2):152-60; quiz 161. PubMed ID: 25754716
[TBL] [Abstract][Full Text] [Related]
10. Selection of Biologics in Severe Asthma: A Multifaceted Algorithm.
Dávila I; Quirce S; Olaguibel JM
J Investig Allergol Clin Immunol; 2019; 29(4):325-328. PubMed ID: 30969172
[No Abstract] [Full Text] [Related]
11. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
Parulekar AD; Kao CC; Diamant Z; Hanania NA
Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
[TBL] [Abstract][Full Text] [Related]
12. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers.
Santus P; Saad M; Damiani G; Patella V; Radovanovic D
Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886
[TBL] [Abstract][Full Text] [Related]
13. Biologic and New Therapies in Asthma.
Tabatabaian F; Ledford DK; Casale TB
Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
[TBL] [Abstract][Full Text] [Related]
14. Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach.
Zaffini R; Gotte G; Menegazzi M
Drug Des Devel Ther; 2018; 12():281-293. PubMed ID: 29483769
[TBL] [Abstract][Full Text] [Related]
15. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.
Fajt ML; Wenzel SE
J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302
[TBL] [Abstract][Full Text] [Related]
16. How to compare the efficacy of biologic agents in asthma.
Viswanathan RK; Busse WW
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):137-149. PubMed ID: 32387169
[TBL] [Abstract][Full Text] [Related]
17. Severe asthma: what is new in the new millennium.
Ntontsi P; Samitas K; Zervas E; Gaga M
Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
[TBL] [Abstract][Full Text] [Related]
18. Controversies and opportunities in severe asthma.
Humbert M; Busse W; Hanania NA
Curr Opin Pulm Med; 2018 Jan; 24(1):83-93. PubMed ID: 29059087
[TBL] [Abstract][Full Text] [Related]
19. Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.
Silkoff PE; Strambu I; Laviolette M; Singh D; FitzGerald JM; Lam S; Kelsen S; Eich A; Ludwig-Sengpiel A; Hupp GC; Backer V; Porsbjerg C; Girodet PO; Berger P; Leigh R; Kline JN; Dransfield M; Calhoun W; Hussaini A; Khatri S; Chanez P; Susulic VS; Barnathan ES; Curran M; Das AM; Brodmerkel C; Baribaud F; Loza MJ
Respir Res; 2015 Nov; 16():142. PubMed ID: 26576744
[TBL] [Abstract][Full Text] [Related]
20. Choice of biologics in asthma endotypes.
Wangberg H; Woessner K
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
